UPDATE 1-Merck KGaA open to taking part in ImClone bid FRANKFURT, Sept 30 (Reuters) - Merck KGaA would not bid for ImClone Systems Inc on its own, but may consider taking part in a potential approach for the U.S.drugmaker, Merck's Chief Executive Karl-Ludwig Kley said.
'We are not the white...
UPDATE 1-Merck KGaA open to taking part in ImClone bid FRANKFURT, Sept 30 (Reuters) - Merck KGaA would not bid for ImClone Systems Inc on its own, but may consider taking part in a potential approach for the U.S.drugmaker, Merck's Chief Executive Karl-Ludwig Kley said.
'We are not the white...
Merck KGaA open to taking part in ImClone bid FRANKFURT (Reuters) - Merck KGaA would not bid for ImClone Systems Inc on its own, but may consider taking part in a potential approach for the U.S.drugmaker, Merck's Chief Executive Karl-Ludwig Kley said.
'We are not the white knight ....
Merck's Phase IIIb multiple sclerosis study meets endpoint The primary objective of the Improve study was to evaluate the efficacy of the new formulation of Rebif, compared to placebo, in patients with relapsing-remitting multiple sclerosis (RRMS) and active disease by means of magnetic...
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With Study Meets Primary Endpoint by Demonstrating Significant Effect of new Formulation of Rebif(R) on Disease Activity as Measured by MRI After 16 Weeks of TreatmentData Presented at Late-Breaking Session of the World Congress on Treatment and...
Merck KGaA Rebif trial meets endpoint _ Merck KGaA Rebif trial meets endpoint.
Merck's IMPROVE study meets primary endpoints Merck KGaA and its division Merck Serono announced that the ongoing IMPROVE (Investigating MRI Parameters with Rebif imprOVEd formulation) study met its primary endpoint.The primary objective of the study was to evaluate the...
Primary Endpoint Met in Merck Serono’s MS Trial Merck Serono received promising findings from its Phase IIIb study using a new formulation of Rebif in patients with relapsing-remitting multiple sclerosis (MS).The two-arm, randomized, double-blind, controlled, multicenter,...
Results from IMPROVE study show therapeutic effect of new formulation of Rebif(R) at 16 weeks in patients with Study Meets Primary Endpoint by Demonstrating Significant Effect of new Formulation of Rebif(R) on Disease Activity as Measured by MRI After 16 Weeks of Treatment Data Presented at Late-Breaking Session of the World Congress on Treatment and...
Merck KGaA: Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif at 16 Weeks in Pati Study meets primary endpoint by demonstrating significant effect of new formulation of Rebif on disease activity as measured by MRI after 16 weeks of treatment Data presented at late breaking session of the World Congress on Treatment...
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With Formulation of Rebif(R) on Disease Activity as Measured by MRI After 16 Weeks of Treatment - Data Presented at Late-Breaking Session of the World Congress on Treatment and Research in Multiple Sclerosis in Montreal, Canada GENEVA,...
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With GENEVA, Switzerland, September 22 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the ongoing IMPROVE (Investigating MRI Parameters with Rebif imprOVEd formulation) study met its primary...
Merck says results of Rebif encouraging Singapore, Sept 22, 2008: Germanys Merck and its division Merck Serono say the ongoing IMPROVE (Investigating MRI Parameters with Rebif imprOVEd formulation) study met its primary endpoint.A company release said the primary...
Merck KGaA: Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif at 16 Weeks in Pati Study meets primary endpoint by demonstrating significant effect of new formulation of Rebif on disease activity as measured by MRI after 16 weeks of treatment Data presented at late breaking session of the World Congress on Treatment...
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With -- Study meets primary endpoint by demonstrating significant effect of new formulation of Rebif(R) on disease activity as measured by MRI after 16 weeks of treatment -- Data presented at late-breaking session of the World Congress on...
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With - Study Meets Primary Endpoint by Demonstrating Significant Effect of new Formulation of Rebif(R) on Disease Activity as Measured by MRI After 16 Weeks of Treatment - Data Presented at Late-Breaking Session of the World Congress on Treatment...
Results From IMPROVE Study Show Therapeutic Effect of New GENEVA, Switzerland, September 22 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the ongoing IMPROVE (Investigating MRI Parameters with Rebif imprOVEd formulation) study met its primary...
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With GENEVA, Switzerland, September 22 /PRNewswire/ -- - Study Meets Primary Endpoint by Demonstrating Significant Effect of new Formulation of Rebif(R) on Disease Activity as Measured by MRI After 16 Weeks of Treatment - Data Presented at Late...
Results From IMPROVE Study Show Therapeutic Effect of New Formulation - Study Meets Primary Endpoint by Demonstrating Significant Effect of new Formulation of Rebif(R) on Disease Activity as Measured by MRI After 16 Weeks of Treatment - Data Presented at Late-Breaking Session of the World Congress on Treatment...
BRIEF-Merck says results from study show therapeutic effect FRANKFURT, Sept 22 (Reuters) - Merck KGaA: * Says results from improve study show therapeutic effect of new formulation of rebif at 16 weeks in patients with multiple sclerosis ((Frankfurt Newsroom; +49 69 7565 1272)) tf.TFN-Europe...
Bayer says early Betaferon use most effective FRANKFURT (Reuters) - Bayer's multiple sclerosis (MS) treatment Betaferon was shown to be more effective when given on the first sign of the disease than if treatment is delayed, the German drugmaker said on Saturday.Compared to initial...
Bayer says early Betaferon use most effective FRANKFURT (Reuters) - Bayer's multiple sclerosis (MS) treatment Betaferon was shown to be more effective when given on the first sign of the disease than if treatment is delayed, the German drugmaker said on Saturday.Compared to initial...
Bayer says early Betaferon use most effective FRANKFURT (Reuters) - Bayer's multiple sclerosis (MS) treatment Betaferon was shown to be more effective when given on the first sign of the disease than if treatment is delayed, the German drugmaker said on Saturday.Compared to initial...
Merck Serono initiates Phase III multiple sclerosis trial The trial, called Oracle MS will evaluate the safety and efficacy of two dosage regimens of cladribine tablets versus placebo in the treatment of patients who have experienced a first clinical event suggestive of multiple sclerosis (MS).
Merck KGaA Completes Enrollment in the REFLEX Trial of Rebif in Patients at Risk of Developing Multiple Sclero Merck KGaA announced today that its Merck Serono division has completed patient enrollment in the REFLEX trial (REbif FLEXible dosing in early multiple sclerosis).This randomized, double-blind, placebo-controlled, international...
